Dyadic International (DYAI) Non Operating Income (2018 - 2026)
Dyadic International (DYAI) posted Non Operating Income of -$51990.0 for Q1 2026, down 65.79% sequentially from -$31359.0 in Q4 2025, and down 107.1% YoY from $732411.3 in Q1 2025.
Dyadic International (DYAI) Non Operating Income (2018 - 2026) Analysis & Trends
Dyadic International has reported Non Operating Income for 9 years, with the latest figure at -$51990.0 in Q1 2026.
- Quarterly Non Operating Income fell 107.1% year-over-year to -$51990.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198698.0 (down 302.2% YoY) and the FY2025 annual result came in at -$171812.0, down 287.44% from the prior year.
- Non Operating Income retreated to -$51990.0 in Q1 2026 per DYAI's latest filing, from -$31359.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.1 million in Q1 2023 and troughed at -$64706.0 in Q2 2025.
- A 5-year average of $101915.2 and a median of $2968.0 in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 36761.52% in 2023, then plunged 5886.17% in 2025.
- Over 5 years, Non Operating Income stood at $343143.0 in 2022, then slumped by 71.76% to $96899.0 in 2023, then slumped by 121.49% to -$20821.0 in 2024, then sank by 50.61% to -$31359.0 in 2025, then slumped by 65.79% to -$51990.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$51990.0, -$31359.0, and -$50643.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -51,990.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51,990.00 |
| Dec 31, 2025 | -31,359.00 |
| Sep 30, 2025 | -50,643.00 |
| Jun 30, 2025 | -64,706.00 |
| Mar 31, 2025 | -25,104.00 |
| Dec 31, 2024 | -20,821.00 |
| Sep 30, 2024 | -846.00 |
| Jun 30, 2024 | -2,632.00 |
| Mar 31, 2024 | 115,962.00 |
| Dec 31, 2023 | 96,899.00 |
| Sep 30, 2023 | 105,862.00 |
| Jun 30, 2023 | 137,467.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 343,143.00 |
| Sep 30, 2022 | 54,300.00 |
| Jun 30, 2022 | 30,009.00 |
| Mar 31, 2022 | 2,968.00 |
| Dec 31, 2021 | 1,932.00 |
| Sep 30, 2021 | 1.61 Mn |
| Jun 30, 2021 | 20,900.00 |